Camden Capital LLC reduced its holdings in Johnson & Johnson (NYSE: JNJ – Get Rating) by 69.1% during the 4th quarter, HoldingsChannel reports. The firm owned 3,544 shares of the company stock after selling 7,934 shares during the quarter. Camden Capital LLC’s holdings in Johnson & Johnson were worth $ 606,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Ulland Investment Advisors LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $ 296,000. Castle Rock Wealth Management LLC grew its position in Johnson & Johnson by 3.9% during the fourth quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company stock worth $ 2,119,000 after buying an additional 479 shares in the last quarter. Lynch Asset Management Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $ 1,625,000. Richwood Investment Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $ 664,000. Finally, Oak Harvest Investment Services grew its position in Johnson & Johnson by 15.3% during the fourth quarter. Oak Harvest Investment Services now owns 28,502 shares of the company stock worth $ 4,876,000 after buying an additional 3,789 shares in the last quarter. 68.78% of the stock is currently owned by institutional investors.
NYSE: JNJ opened at $ 169.46 on Friday. Johnson & Johnson has a 1 year low of $ 155.72 and a 1 year high of $ 186.69. The firm has a 50 day moving average of $ 178.10 and a 200-day moving average of $ 172.79. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $ 445.92 billion, a P / E ratio of 22.84, a price-to-earnings-growth ratio of 3.36 and a beta of 0.66.
Johnson & Johnson (NYSE: JNJ – Get Rating) last posted its earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $ 2.60 by $ 0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company had revenue of $ 23.43 billion during the quarter, compared to analysts’ expectations of $ 23.62 billion. During the same quarter in the previous year, the company posted $ 2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.0% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a $ 1.13 dividend. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 dividend on an annualized basis and a dividend yield of 2.67%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $ 1.06. Johnson & Johnson’s payout ratio is 60.92%.
In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $ 180.00, for a total value of $ 1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $ 2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Hait sold 29,699 shares of the business’s stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares of the company stock, valued at approximately $ 14,729,724.88. The disclosure for this sale can be found here. Insiders sold 78,161 shares of company stock valued at $ 13,895,302 in the last quarter. 0.35% of the stock is currently owned by corporate insiders.
A number of equities research analysts recently weighed in on JNJ shares. Bank of America started coverage on Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating on the stock. Citigroup decreased their target price on Johnson & Johnson from $ 210.00 to $ 205.00 in a research report on Tuesday, May 17th. Morgan Stanley decreased their price objective on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Credit Suisse Group lifted their price objective on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Finally, Raymond James lifted their price objective on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $ 190.50.
Johnson & Johnson Company Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.